We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
US and UK regulators say diabetes medication showed ‘significant’ weight loss benefits
Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier
Biotech acquisitions this year intended to cement position as market leaders in weight-loss field
Cheaper valuations have finally drawn back cash-rich pharmaceutical makers
Point is developing radioligand molecules that can deliver targeted radiation to tumour cells
BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances
Low-cost domestic rivals hope to challenge Novo Nordisk in one of world’s biggest markets for anti-obesity medication
US pharmaceutical group says it wants to become the first trillion dollar healthcare company
Drugs that tackle obesity, diabetes and heart disease are good for profits and the public
Shares in Danish drugmaker and US rival Eli Lilly surge to record highs after positive trial of weight-loss drug
Novo Nordisk and Eli Lilly accused of failing to warn patients of gastroparesis risk
Promising trial results will not end scientific debate over the disease, but they further validate pharmaceutical research
Dementia experts hail ‘watershed moment’ after trial results for donanemab antibody treatment
German group aims to join companies whose fortunes have been transformed by weight loss treatments
Manufacturers racing to build what could be one of industry’s biggest markets must tread with care
In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide
Clinical study results could boost patient access to new class of treatment
US pharma group’s late-stage study has shown treatment can slash body weight by nearly a sixth
Corporate America faces its sharpest drop in profits since the beginning of the Covid pandemic
Chief executive says draft plan to cut market exclusivity protection could make pursuing some treatments unviable
Pharma group’s decision comes in response to US political pressure over high cost of diabetes medication
AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances
Chief executive claims Republican state government ‘rushed’ process when passing sweeping restrictions
International Edition
